What is Rasio?
Rasio Therapeutics, Inc. is a biopharmaceutical company based in Maryland, leveraging cutting-edge computer-aided drug design technology to pioneer new therapeutic approaches. The company has established a strategic partnership with SilcsBio, a recognized leader in computational drug discovery, to engineer small molecules targeting challenging disease indications. Rasio's initial focus is on the oncology sector, aiming to address areas with substantial unmet medical needs.
How much funding has Rasio raised?
Rasio has raised a total of $1.5M across 1 funding round:
Unspecified
$1.5M
Unspecified (2021): $1.5M with participation from Bluedot Bio
Key Investors in Rasio
Bluedot Bio
Bluedot Bio is an investor participating in the funding round, likely focused on biotechnology or pharmaceutical ventures.
What's next for Rasio?
The recent major enterprise-level funding positions Rasio Therapeutics for accelerated development and scaling of its innovative drug design platform. This capital infusion is expected to fuel the advancement of its oncology therapeutics pipeline, potentially enabling the company to move from design and development into preclinical and clinical stages. The strategic investment signals strong investor confidence in Rasio's technology and its potential to disrupt the biopharmaceutical landscape.
See full Rasio company page
